Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature

被引:0
作者
Laiyan Zhou
Mai Zhang
Rui Li
Jianxin Xue
You Lu
机构
[1] Sichuan University,Department of Thoracic Cancer, Cancer Center, West China Hospital, West China School of Clinical Medicine
来源
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词
Immunotherapy; Pseudoprogression; Hyperprogression; Lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3269 / 3279
页数:10
相关论文
共 329 条
[1]  
Albert NL(2016)Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas Neuro Oncol 18 1199-1208
[2]  
Weller M(1976)Serial bone scanning using technetium 99m diphosphonate in patients undergoing cyclical combination chemotherapy for advanced breast cancer Clin Nucl Med 1 13-17
[3]  
Suchorska B(2017)Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer Lung Cancer 106 1-7
[4]  
Alexander JL(2018)Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation J Thorac Dis 10 2166-2178
[5]  
Gillespie PJ(2018)Pitfalls in the radiological response assessment of immunotherapy Memo 11 138-143
[6]  
Edelstyn GA(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026
[7]  
Bagley SJ(2018)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Nat Med 24 1852-1858
[8]  
Kothari S(2018)New developments in brain metastases Ther Adv Neurol Disord 11 1756286418785502-iv372
[9]  
Aggarwal C(2014)1070P Adaptation of the immune-related response criteria: irRECIST Ann Oncol 25 iv361-396
[10]  
Barrón F(2019)Novel patterns of response under immunotherapy Ann Oncol 30 385-1639